Developing etanercept - a copycat of biotech giant Amgen Inc.’s blockbuster drug Enbrel - with Japanese joint-venture partner Yoshindo, has been part of Lupin Ltd.’s stepped-up transition to complex generics, speciality medicines and biosimilars to generate new revenue sources that go beyond an increasingly congested and competitive plain-vanilla generic market. Lupin is seen by analysts as playing catch-up with its Indian peers in building a complex generic pipeline.
YLB, Lupin’s and Yoshindo’s joint venture, reported a “successful outcome” from its global Phase III clinical trial of etanercept involving...
